Uy Ear
Stock Analyst at Mizuho
(0.99)
# 2088
Out of 5,347 analysts
70
Total ratings
35.71%
Success rate
5.66%
Average return
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
ACAD ACADIA Pharmaceutica... | Maintains: Neutral | 20 23 | 21.57 | 6.63% | 11 | May 19, 2025 | |
TECX Tectonic Therapeutic | Maintains: Outperform | 51 85 | 21.48 | 295.72% | 2 | May 15, 2025 | |
ARQT Arcutis Biotherapeut... | Maintains: Outperform | 20 21 | 13.03 | 61.17% | 14 | Feb 26, 2025 | |
QURE uniQure | Maintains: Neutral | 7 20 | 14.47 | 38.22% | 4 | Dec 19, 2024 | |
RLMD Relmada Therapeutics | Downgrades: Neutral | 23 1 | 0.75 | 33.33% | 1 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 35 40 | 30.61 | 30.68% | 5 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 18 16 | 6.45 | 148.06% | 2 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 40 | 9.58 | 317.54% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 145 179 | 37.59 | 376.19% | 5 | May 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 20 23 | 9.19 | 150.27% | 3 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 116 140 | 122.95 | 13.87% | 10 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 60 24 | n/a | n/a | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 35 16 | n/a | n/a | 1 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 4 3 | n/a | n/a | 2 | Aug 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 36 40 | 155.02 | -74.2% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 2 | n/a | n/a | 1 | Mar 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 10 | 1.86 | 437.63% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 5 3 | 0.84 | 257.14% | 2 | Mar 1, 2023 |